Cerus Corp Dossier - Source-backed chat

Cerus Corp

CERSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.49

Intrinsic Value $2.57median of 2 methodsbased on filings through 30 Jun 2026

Market Price $2.32Price as of 1 Oct 2026

Near fair valueIntrinsic value is 11% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $467.5M

Enterprise Value $514.6M

Shares Outstanding 198.8M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cerus Corporation is transitioning from a high-burn development-stage biotech into a sustainable, high-growth commercial enterprise. Driven by its core platelet franchise and the rapid adoption of the INTERCEPT Fibrinogen Complex (IFC) in the U.S., the company has achieved eight consecutive quarters of positive adjusted EBITDA. With a major leadership transition on July 1, 2026, elevating COO Vivek Jayaraman to CEO, and a robust pipeline of near-term catalysts (including the INT200 PMA submission and the Phase 3 RedeS RBC readout), Cerus is well-positioned to unlock significant shareholder value from its currently discounted valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.67

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects regulatory delays or commercial execution hurdles. If the FDA requests additional clinical data for the INT200 device or if the RedeS Phase 3 trial fails to meet its primary endpoints, the commercial timeline for RBCs will be pushed back. High leverage under the new $110M MidCap Financial debt facility could stress the balance sheet if revenue growth slows below double digits.

Base CaseCentral scenario

The base case assumes Cerus successfully executes its commercial strategy, meeting its raised 2026 product revenue guidance of $227M to $231M. Growth is supported by the Blood Centers of America (BCA) partnership and the renewed EFS contract in France. The company maintains positive adjusted EBITDA and submits the INT200 PMA on schedule, paving the way for a U.S. launch in H1 2027.

Bull CaseUpside scenario

Cerus Corp's bull case is driven by strong commercial execution of its core INTERCEPT Blood System, particularly with robust platelet kit demand and rapid adoption of the INTERCEPT Fibrinogen Complex (IFC). The company has demonstrated significant top-line growth (Q1 2026 product revenue up 24% YoY) and raised its full-year 2026 product revenue guidance to $227M-$231M. Financial sustainability is improving, highlighted by a swing to positive adjusted EBITDA ($4M in Q1 2026) and a newly secured debt facility with MidCap Financial that reduces annual interest expenses. Additionally, its late-stage red blood cell (RBC) program (with RedeS Phase 3 readouts expected by Q4 2026) provides high-upside optionality.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with Q1 2026 product revenue up 24% YoY, led by platelet kits and a 120% volume surge in IFC.
Improving financial profile with eight consecutive quarters of positive adjusted EBITDA and narrowed GAAP net losses.
Orderly leadership transition with COO Vivek Jayaraman taking over as CEO on July 1, 2026, ensuring commercial continuity.
Substantial near-term catalysts including the INT200 PMA submission in Q2 2026 and the Phase 3 RedeS RBC readout in Q4 2026.

Key Investment Risks

Regulatory risk associated with binary outcomes for the INT200 PMA and European RBC approvals.
High leverage with significant secured debt, though mitigated by the newly closed $110M MidCap Financial facility.
Customer concentration and supply chain vulnerabilities, as adoption relies heavily on a select network of blood centers.

Thesis Invalidation Triggers

Failure or significant delay of the INT200 FDA PMA submission or clearance.
Negative or inconclusive clinical data from the Phase 3 RedeS RBC study in Q4 2026.
A material drop in product gross margins below the low-50s range due to persistent inflationary or supply chain pressures.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.